Healthy Volunteers Clinical Trial
Official title:
Supporting High-intensity Interval Training With Mindfulness for Enhancing Childhood Executive Function
The goal of this randomized controlled trial is to learn about the effect of a 12-week school-based intervention combining mindfulness with high-intensity interval training (MF-HIIT), MF-only intervention, and HIIT-only intervention in relative to sedentary activities on executive function (EF) in 10-12 years old children. The main question it aims to answer is whether a 12-week school-based MF-HIIT intervention has larger beneficial effect on EF performance than that following a 12-week school-based MF-only and HIIT-only in relative to the sedentary activities. Multiple cohorts of participants will be recruited to participate this one-semester study, including the pretest, intervention, and posttest phases. During the pretest phase, participants an their parents will complete the following 1. Kaufman Brief Intelligence Test (KBIT) to assess intelligence quotient 2. Fitnessgram test to assess aerobic capacity, muscle endurance, flexibility, and body mass index 3. Child and Adolescent Mindfulness Measure (CAMM) questionnaire to assess dispositional mindfulness 4. Computerized tasks to assess EF 5. Parent-reported demographic and health information Following the pretest phase, participants will receive the 12-week classroom-based intervention, with the classroom as the intervention unit. Following the intervention and during the posttest phase, participants will complete the fitness, measures, EF measures, and dispositional mindfulness measure again. Researcher will compare the EFn outcome measures following the MF-HIIT, MF-only, and HIIT-only interventions with the sedentary activity intervention to see if MF and HIIT has beneficial effects on children's EF. Further, researcher will compare the EF measures following the MF-HIIT compared with MF-only and HIIT-only interventions to see if combining MF with HIIT has greater beneficial effects on children's EF than MF and HIIT alone.
Status | Not yet recruiting |
Enrollment | 352 |
Est. completion date | May 31, 2026 |
Est. primary completion date | May 31, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 10 Years to 12 Years |
Eligibility | Inclusion Criteria: - Age between 10-12 years old - Intelligence Quotient = 85 - Capable of performing exercise based on pre-participation health screening - No formal diagnosis of cognitive disorders (e.g., attention deficit hyperactivity disorder) and neurological diseases (e.g., epilepsy) Exclusion Criteria: - Age outside of the range of 10-12 years old - Intelligence Quotient < 85 - No capable of performing exercise based on pre-participation health screening - Has formal diagnosis of cognitive disorders (e.g., attention deficit hyperactivity disorder) and neurological diseases (e.g., epilepsy) |
Country | Name | City | State |
---|---|---|---|
United States | Purdue University | West Lafayette | Indiana |
Lead Sponsor | Collaborator |
---|---|
Purdue University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Inhibition speed | Inhibition speed will be assessed by the response time (ms) during a child-friendly flanker task. | At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends | |
Primary | Inhibition accuracy | Inhibition accuracy will be assessed by the response accuracy (percent) during a child-friendly flanker task. | At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends | |
Primary | Updating speed | Updating speed will be assessed by the response time (ms) during a child-friendly n-back task. | At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends | |
Primary | Updating accuracy | Updating accuracy will be assessed by the response accuracy (percent) during a child-friendly n-back task. | At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends | |
Primary | Shifting speed | Shifting speed will be assessed by the response time (ms) during a child-friendly switching task. | At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends | |
Primary | Shifting accuracy | Shifting accuracy will be assessed by the response accuracy (percent) during a child-friendly switching task. | At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends | |
Secondary | Aerobic capacity | Aerobic capacity will be assessed by the Progressive Aerobic Cardiovascular Endurance Run (PACER) test | At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends | |
Secondary | Upper body muscle endurance | Upper body muscle endurance will be assessed by the push-ups test | At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends | |
Secondary | Core body muscle endurance | Core body muscle endurance will be assessed by the curl-ups test | At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends | |
Secondary | Flexibility | Flexibility will be assessed by the back-saver sit and reach test | At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends | |
Secondary | Body composition | body composition will be assessed by the body mass index computed as weight (kg) / (height [m] * height [m]) | At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends | |
Secondary | Dispositional mindfulness | Dispositional mindfulness will be assessed by the Child and Adolescent Mindfulness Measure questionnaire (CAMM). The questionnaire has 10 items and requires the respondents to rating each item using a 5-point likert scale from 0 (Never True) to 4 (Always True). Higher summed scores indicate higher levels of mindfulness | At the baseline (1-2 weeks) before intervention starts and after (1-2 weeks) the intervention ends |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |